Shots:
- Alvotech reported positive top-line data from the AVT80-GL-P01 PK study comparing AVT80 with Entyvio in healthy adults
- The study met all 1EP, demonstrating PK similarity between AVT80 & Entyvio following a single 108mg/0.68mL SC dose, supporting AVT80’s biosimilar profile
- Alvotech is developing AVT16 (IV) & AVT80 (SC) as Entyvio’s biosimilars, with the AVT80-GL-P01 study demonstrating PK similarity across both routes & serving as a pivotal trial to support clinical similarity for both candidates based on regulatory advice
Ref: Globenewswire | Image: Alvotech | Press Release
Related News: Alvotech and Sandoz Partner to Expand Access to Biosimilars Across Canada, Australia, & New Zealand
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
